Comparative Pharmacology
Head-to-head clinical analysis: FOLOTYN versus MAVENCLAD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLOTYN versus MAVENCLAD.
FOLOTYN vs MAVENCLAD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Terminal elimination half-life of cladribine is approximately 5.7 days (range 4-10 days) following oral administration. This long half-life supports once-daily high-dose short-course dosing and is due to slow release from lymphocytes. Clinical context: Allows sustained intracellular levels of active triphosphate in lymphocytes.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Approximately 100% of cladribine dose is eliminated via renal excretion of unchanged drug and metabolites, with <5% recovered in feces. Renal clearance is about 2/3 of total clearance. Biliary elimination is negligible.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent